Attention deficit-hyperactivity disorder, susceptibility to, 7

Summary

Attention deficit-hyperactivity disorder, susceptibility to, 7 (MONDO:0013076) is a disease with 3 cohort genes.

At a glance

• Cohort genes: 3
• ClinVar variants: 6

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	attention deficit-hyperactivity disorder, susceptibility to, 7
Mondo ID	MONDO:0013076
OMIM	613003
UMLS	C2751802
MedGen	416637
Is cancer (heuristic)	no

Also known as: ADHD7 · attention deficit-hyperactivity disorder, susceptibility to, 7 · attention Deficit-hyperactivity disorder, susceptibility to, type 7

Data availability: 6 ClinVar variants · 1 GenCC gene-disease record.

Disease family

Classification path: disease susceptibility › inherited disease susceptibility › attention deficit-hyperactivity disorder, susceptibility to, 7

Related subtypes (283): microvascular complications of diabetes, susceptibility, Mycobacterium tuberculosis, susceptibility, bacteremia, susceptibility, pregnancy loss, recurrent, susceptibility, autoimmune thyroid disease, susceptibility to, susceptibility to HIV infection, appendicitis, proneness to, atherosclerosis susceptibility, multiple sclerosis, susceptibility to, dyslexia, susceptibility to, 1, endometriosis, susceptibility to, 1, osteoarthritis susceptibility 2, essential hypertension, genetic, osteoarthritis susceptibility 1, otitis media, susceptibility to, pelvic organ prolapse, susceptibility to, pulmonary edema of mountaineers, susceptibility to, sarcoidosis, susceptibility to, 1, strabismus, susceptibility to, thyrotoxic periodic paralysis, susceptibility to, 1, predisposition to invasive fungal disease due to CARD9 deficiency, celiac disease, susceptibility to, 1, hemolytic uremic syndrome, atypical, susceptibility to, 1, hypervitaminosis a, susceptibility to, kuru, susceptibility to, leprosy, susceptibility to, 3, nonarteritic anterior ischemic optic neuropathy, susceptibility to, diabetes mellitus, insulin-dependent, X-linked, susceptibility to, coronary heart disease, susceptibility to, 3, dyslexia, susceptibility to, 9, systemic lupus erythematosus, susceptibility to, 15, Leber optic atrophy, susceptibility to, dyslexia, susceptibility to, 2, Helicobacter pylori infection, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 1, inherited susceptibility to asthma, renal dysplasia, cystic, susceptibility to, systemic lupus erythematosus, susceptibility to, 1, leishmaniasis, tegumentary, susceptibility to, xanthomatosis, susceptibility to, hyperlipidemia, combined, 1, urinary tract infections, recurrent, susceptibility to, hypertension, essential, susceptibility to, 1, hepatic fibrosis, severe, susceptibility to, due to Schistosoma mansoni infection, dyslexia, susceptibility to, 3, Ascaris lumbricoides infection, susceptibility to, hypertension, essential, susceptibility to, 2, epilepsy, idiopathic generalized, susceptibility to, 7, systemic lupus erythematosus, susceptibility to, 2, systemic lupus erythematosus, susceptibility to, 3, nephrolithiasis, uric acid, susceptibility to, atrioventricular septal defect, susceptibility to, 2, vitiligo-associated multiple autoimmune disease susceptibility 1, polysubstance abuse, susceptibility to, dyslexia, susceptibility to, 6, glaucoma, normal tension, susceptibility to, anorexia nervosa, susceptibility to, 1, stroke, susceptibility to, 1, dyslexia, susceptibility to, 5, epilepsy, idiopathic generalized, susceptibility to, 2, familial meningioma, celiac disease, susceptibility to, 5, systemic lupus erythematosus with hemolytic anemia, susceptibility to, 1, hypertension, essential, susceptibility to, 3, coronary heart disease, susceptibility to, 1, bulimia nervosa, susceptibility to, 1, leprosy, susceptibility to, 2, epilepsy, idiopathic generalized, susceptibility to, 9, Parkinson disease 11, autosomal dominant, susceptibility to, focal segmental glomerulosclerosis 3, susceptibility to, autoimmune disease, susceptibility to, 1, osteoarthritis susceptibility 3, systemic lupus erythematosus with nephritis, susceptibility to, 1, systemic lupus erythematosus with nephritis, susceptibility to, 2, systemic lupus erythematosus with nephritis, susceptibility to, 3, coronary heart disease, susceptibility to, 2, coronary heart disease, susceptibility to, 4, autoimmune disease, susceptibility to, 2, autoimmune disease, susceptibility to, 3, systemic lupus erythematosus, susceptibility to, 4, myocardial infarction, susceptibility to, major depressive disorder 1, legionnaire disease, susceptibility to, myocardial infarction, susceptibility to, 2, major depressive disorder 2, hypertension, essential, susceptibility to, 4, epilepsy, idiopathic generalized, susceptibility to, 3, myoclonic epilepsy, juvenile, susceptibility to, 3, orofacial cleft 6, susceptibility to, coronary heart disease, susceptibility to, 5, attention deficit-hyperactivity disorder, susceptibility to, 1, attention deficit-hyperactivity disorder, susceptibility to, 2, attention deficit-hyperactivity disorder, susceptibility to, 3, attention deficit-hyperactivity disorder, susceptibility to, 4, Alzheimer disease 9, susceptibility to respiratory infections associated with CD8alpha chain mutation, dyslexia, susceptibility to, 8, autoimmune disease, susceptibility to, 4, hepatitis C virus, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 4, celiac disease, susceptibility to, 4, celiac disease, susceptibility to, 2, celiac disease, susceptibility to, 3, leprosy, susceptibility to, 1, systemic lupus erythematosus, susceptibility to, 5, systemic lupus erythematosus, susceptibility to, 6, opioid dependence, susceptibility to, 1, systemic lupus erythematosus, susceptibility to, 7, systemic lupus erythematosus, susceptibility to, 8, hypertension, essential, susceptibility to, 5, hypertension, essential, susceptibility to, 6, Parkinson disease 13, autosomal dominant, susceptibility to, West Nile virus, susceptibility to, hepatitis B virus, susceptibility to, Buruli ulcer, susceptibility to, osteoarthritis susceptibility 4, systemic lupus erythematosus, susceptibility to, 9, coronary heart disease, susceptibility to, 7, hypertension, essential, susceptibility to, 7, leprosy, susceptibility to, 4, hypertension, essential, susceptibility to, 8, epilepsy, idiopathic generalized, susceptibility to, 13, coronary heart disease, susceptibility to, 8, myoclonic epilepsy, juvenile, susceptibility to, 4, susceptibility to visceral leishmaniasis, 2, susceptibility to visceral leishmaniasis, 3, celiac disease, susceptibility to, 6, epilepsy, idiopathic generalized, susceptibility to, 5, epilepsy, childhood absence, susceptibility to, 6, celiac disease, susceptibility to, 7, celiac disease, susceptibility to, 8, celiac disease, susceptibility to, 9, celiac disease, susceptibility to, 10, celiac disease, susceptibility to, 11, celiac disease, susceptibility to, 12, celiac disease, susceptibility to, 13, coronary heart disease, susceptibility to, 9, systemic lupus erythematosus, susceptibility to, 10, systemic lupus erythematosus, susceptibility to, 11, systemic lupus erythematosus, susceptibility to, 12, epilepsy, childhood absence, susceptibility to, 5, attention deficit-hyperactivity disorder, susceptibility to, 5, attention deficit-hyperactivity disorder, susceptibility to, 6, systemic lupus erythematosus, susceptibility to, 13, sarcoidosis, susceptibility to, 2, sarcoidosis, susceptibility to, 3, osteoarthritis susceptibility 5, osteoarthritis susceptibility 6, focal segmental glomerulosclerosis 4, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 8, herpes simplex encephalitis, susceptibility to, 2, epilepsy, idiopathic generalized, susceptibility to, 10, pelvic organ prolapse, susceptibility to, 2, systemic lupus erythematosus, susceptibility to, 14, leprosy, susceptibility to, 5, thyrotoxic periodic paralysis, susceptibility to, 2, hearing loss, cisplatin-induced, susceptibility to, susceptibility to mononeuropathy of the median nerve, mild, fatty liver disease, nonalcoholic, susceptibility to, 2, leprosy, susceptibility to, 6, autoimmune disease, susceptibility to, 6, Parkinson disease 5, autosomal dominant, susceptibility to, aspergillosis, susceptibility to, sick sinus syndrome 3, susceptibility to, Parkinson disease 18, autosomal dominant, susceptibility to, epilepsy, juvenile myoclonic, susceptibility to, 9, dengue virus, susceptibility to, coronary heart disease, susceptibility to, 6, podoconiosis, susceptibility to, peripartum cardiomyopathy, susceptibility to, influenza, severe, susceptibility to, thyrotoxic periodic paralysis, susceptibility to, 3, human herpesvirus 8, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 12, herpes simplex encephalitis, susceptibility to, 3, herpes simplex encephalitis, susceptibility to, 4, pulmonary hypertension, neonatal, susceptibility to, craniosynostosis 5, susceptibility to, melioidosis, susceptibility to, chronic mountain sickness, susceptibility to, herpes simplex encephalitis, susceptibility to, 7, epilepsy, idiopathic generalized, susceptibility to, 14, hereditary neoplastic syndrome, autosomal recessive Mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR1 deficiency, autosomal recessive Mendelian susceptibility to mycobacterial diseases due to partial IFNgammaR2 deficiency, susceptibility to localized juvenile periodontitis, inherited susceptibility to mycobacterial diseases, neural tube defects, susceptibility to, multiple system atrophy 1, susceptibility to, nephrolithiasis susceptibility caused by SLC26A1, myoclonic epilepsy, juvenile, susceptibility to, 1, epilepsy, childhood absence, susceptibility to, 1, autism, susceptiblity to, susceptibility to visceral leishmaniasis, 1, malaria, susceptibility to, spondyloarthropathy, susceptibility to, herpes simplex encephalitis, susceptibility to, 1, epilepsy, idiopathic generalized, susceptibility to, 18, epilepsy, idiopathic generalized, susceptibility to, 15, hepatitis, fulminant viral, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 16, autosomal recessive mendelian susceptibility to mycobacterial diseases due to partial jak1 deficiency, aortic aneurysm, familial thoracic 11, susceptibility to, craniosynostosis 7, amyotrophic lateral sclerosis, susceptibility to, 24, amyotrophic lateral sclerosis, susceptibility to, 25, epilepsy, juvenile myoclonic, susceptibility to, 10, susceptibility to angioedema induced by ACE inhibitors, epidermodysplasia verruciformis, susceptibility to, exfoliation syndrome, susceptibility to, basal cell carcinoma, susceptibility to, graft-versus-host disease, susceptibility to, narcolepsy, susceptibility to, pulmonary disease, chronic obstructive, susceptibility to, restless legs syndrome, susceptibility to, psoriasis, susceptibility to, age related macular degeneration, susceptibility to, allergic rhinitis, susceptibility to, dermatitis, atopic, susceptibility to, Hirschsprung disease, susceptibility to, diabetes mellitus, ketosis-prone, schizophrenia, susceptibility to, radioulnar synostosis, nonsyndromic, susceptibility to, lumbar disk herniation, susceptibility to, lumbar disk degeneration, susceptibility to, psoriatic arthritis, susceptibility to, migraine with or without aura, susceptibility to, Alzheimer disease, susceptibility to, mitochondrial, Asperger syndrome, susceptibility to, tobacco addiction, susceptibility to, lipodystrophy, partial, acquired, susceptibility to, Graves disease, susceptibility to, 1, epilepsy, idiopathic generalized, susceptibility to, 17, breast-ovarian cancer, familial, susceptibility to, blepharospasm, benign essential, susceptibility to, hemorrhage, intracerebral, susceptibility to, IgA nephropathy, susceptibility to, hemolytic uremic syndrome, atypical, susceptibility to, 7, vitiligo-associated multiple autoimmune disease susceptibility 6, delayed sleep phase syndrome, susceptibility to, encephalitis, acute, infection-induced, susceptibility to, malignant hyperthermia, susceptibility to, multicentric Castleman disease, susceptibility to, pelvic organ prolapse, susceptibility to, 1, amyotrophic lateral sclerosis, susceptibility to, 13, Graves disease, susceptibility to, X-linked 2, autoimmune thyroid disease, susceptibility to, 5, atrioventricular septal defect, susceptibility to, 1, epilepsy, juvenile myoclonic, susceptibility to, 6, autoimmune disease, susceptibility to, 5, epilepsy, idiopathic generalized, susceptibility to, 6, seasonal affective disorder, susceptibility to, ventricular fibrillation during myocardial infarction, susceptibility to, UV-induced skin damage, susceptibility to, antisocial behavior, susceptibility to, aplastic anemia, susceptibility to, cardiomyopathy, familial hypertrophic, 4, susceptibility to, cirrhosis, noncryptogenic, susceptibility to, coronary artery disease, severe, susceptibility to, dengue fever, susceptibility to, dengue hemorrhagic fever, susceptibility to, dengue shock syndrome, susceptibility to, dyslexia, susceptibility to, 4, dyslexia, susceptibility to, 7, efavirenz central nervous system toxicity, susceptibility to, obesity, susceptibility to, bleeding disorder, platelet-type, 13, susceptibility to, Schistosoma mansoni infection, susceptibility/resistance to, Parkinson disease 24, autosomal dominant, susceptibility to, iron overload, susceptibility to, hydrocephalus, congenital, 5, susceptibility to, hearing loss, noise-induced, susceptibility to, hyperemesis gravidarum, susceptibility to, Parkinson disease 26, autosomal dominant, susceptibility to, epilepsy, idiopathic generalized, susceptibility to, 19, polycystic kidney disease 9, susceptibility to, rhabdomyolysis, susceptibility to, scoliosis, isolated, susceptibility to, dystonia 38, susceptibility to, gallbladder disease 4, epilepsy, juvenile absence, susceptibility to, GBA1-related Parkinson disease, susceptibility, SH2B3-related immune system disorder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

6 retrieved; paginated sample, class counts are floors:

4 uncertain significance, 1 likely benign, 1 risk factor

ClinVar	Variant (HGVS)	Gene	Classification	Review
3163	NM_173353.4(TPH2):c.907C>T (p.Arg303Trp)	TPH2	risk factor	no assertion criteria provided
3731457	NM_000798.5(DRD5):c.1109C>A (p.Ala370Asp)	DRD5	Uncertain significance	criteria provided, single submitter
1334076	NM_173353.4(TPH2):c.983C>G (p.Ala328Gly)	TPH2	Uncertain significance	criteria provided, single submitter
3164	NM_173353.4(TPH2):c.616C>T (p.Pro206Ser)	TPH2	Uncertain significance	criteria provided, multiple submitters, no conflicts
3575264	NM_173353.4(TPH2):c.710G>A (p.Arg237Gln)	TPH2	Uncertain significance	criteria provided, single submitter
310378	NM_173353.4(TPH2):c.122C>A (p.Ser41Tyr)	TPH2	Likely benign	criteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 5 · Orphanet: 1 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

Gene	Classification	Inheritance	Disease	Records
TDO2	Limited	Autosomal dominant	attention deficit-hyperactivity disorder, susceptibility to, 7	4
TPH2	Limited	Autosomal dominant	attention deficit-hyperactivity disorder, susceptibility to, 7

Orphanet rare-disease linkage (cohort genes)

Gene	Orphanet ID	Rare disease
TDO2	Orphanet:2224	Hypertryptophanemia

Cohort genes → proteins

3 cohort genes, 3 distinct canonical proteins.

Evidence partition

Subset	Genes
multi_evidence	3

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
TDO2	HGNC:11708	ENSG00000151790	P48775	Tryptophan 2,3-dioxygenase	gencc,clinvar
TPH2	HGNC:20692	ENSG00000139287	Q8IWU9	Tryptophan 5-hydroxylase 2	gencc,clinvar
DRD5	HGNC:3026	ENSG00000169676	P21918	D(1B) dopamine receptor	clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
TDO2	Tryptophan 2,3-dioxygenase	Heme-dependent dioxygenase that catalyzes the oxidative cleavage of the L-tryptophan (L-Trp) pyrrole ring and converts L-tryptophan to N-formyl-L-kynurenine.
DRD5	D(1B) dopamine receptor	Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.

Protein-family classification

Druggable: 3 · Difficult: 0 · Unknown: 0 · Druggable fraction: 1.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Enzyme (other)	2	8.0×	0.039
GPCR	1	8.0×	0.120

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
TDO2	Enzyme (other)	yes	1.13.11.11	Trp_2_3_dOase, Trp/Indoleamine_2_3_dOase-like
TPH2	Enzyme (other)	yes	1.14.16.4	ArAA_hydroxylase, ACT_dom, Trp_5_mOase
DRD5	GPCR	yes		GPCR_Rhodpsn, Dopamine_D5_rcpt, Dopamine_rcpt

Expression context

Cohort genes with no expression data: 0.

2 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	3
unknown	0

Top tissues across cohort

Tissue	Cohort genes
liver	1
right lobe of liver	1
vermiform appendix	1
male germ line stem cell (sensu Vertebrata) in testis	1
primordial germ cell in gonad	1
secondary oocyte	1
ileal mucosa	1
pancreatic ductal cell	1
tibialis anterior	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
TDO2	127	broad	marker	right lobe of liver, liver, vermiform appendix
TPH2	111	tissue_specific	marker	secondary oocyte, male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad
DRD5	64	tissue_specific	yes	pancreatic ductal cell, tibialis anterior, ileal mucosa

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
TDO2	1,753
TPH2	1,551
DRD5	1,086

Structural data

PDB: 3 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
TDO2	P48775	22
TPH2	Q8IWU9	5
DRD5	P21918	1

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 6. Enrichment computed across 3 evidence-associated genes (3 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Serotonin and melatonin biosynthesis	1	761.3×	0.004	TPH2
Dopamine receptors	1	761.3×	0.004	DRD5
Tryptophan catabolism	1	253.8×	0.008	TDO2
G alpha (s) signalling events	1	24.4×	0.052	DRD5
Metabolism of amino acids and derivatives	1	22.5×	0.052	TDO2
Metabolism	1	3.9×	0.237	TDO2

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 3 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
obsolete negative regulation of NAD(P)H oxidase activity	1	5617.3×	0.002	DRD5
regulation of female receptivity	1	5617.3×	0.002	DRD5
norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure	1	2808.7×	0.002	DRD5
aromatic amino acid metabolic process	1	2808.7×	0.002	TPH2
obsolete L-tryptophan catabolic process to acetyl-CoA	1	2808.7×	0.002	TDO2
response to nitroglycerin	1	2808.7×	0.002	TDO2
sensitization	1	1872.4×	0.002	DRD5
serotonin biosynthetic process	1	1404.3×	0.003	TPH2
regulation of systemic arterial blood pressure by vasopressin	1	1123.5×	0.003	DRD5
positive regulation of adenylate cyclase activity	1	1123.5×	0.003	DRD5
obsolete L-tryptophan catabolic process to L-kynurenine	1	936.2×	0.003	TDO2
cellular response to catecholamine stimulus	1	802.5×	0.003	DRD5
synaptic transmission, dopaminergic	1	702.2×	0.003	DRD5
phospholipase C-activating dopamine receptor signaling pathway	1	702.2×	0.003	DRD5
G protein-coupled dopamine receptor signaling pathway	1	624.1×	0.003	DRD5
response to cortisol	1	561.7×	0.004	TDO2
adenylate cyclase-activating dopamine receptor signaling pathway	1	510.7×	0.004	DRD5
adenylate cyclase-activating adrenergic receptor signaling pathway	1	401.2×	0.004	DRD5
long-term synaptic depression	1	295.6×	0.006	DRD5
transmission of nerve impulse	1	216.1×	0.007	DRD5
negative regulation of blood pressure	1	216.1×	0.007	DRD5
response to cocaine	1	193.7×	0.007	DRD5
response to amphetamine	1	165.2×	0.008	DRD5
associative learning	1	160.5×	0.008	DRD5
reactive oxygen species metabolic process	1	156.0×	0.008	DRD5
protein homotetramerization	1	79.1×	0.015	TDO2
wound healing	1	75.9×	0.016	DRD5
response to ethanol	1	48.9×	0.023	TDO2
intracellular calcium ion homeostasis	1	48.4×	0.023	DRD5
adenylate cyclase-activating G protein-coupled receptor signaling pathway	1	37.7×	0.028	DRD5

Therapeutics

Drug target analysis

Approved (phase 4): 3 · Phase ≥3: 3 · Phased (≥1): 3 · Undrugged: 0

Druggability breadth: 3 of 3 evidence-associated genes (100%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Genes with an approved drug

The molecule shown is one approved compound that hits the gene — not necessarily a drug of choice or one indicated for this disease.

Symbol	Example approved molecule
TDO2	BERBERINE
TPH2	TELOTRISTAT
DRD5	IMIPRAMINE

Top cohort targets by molecule count

Symbol	Molecules	Max phase
DRD5	36	4
TDO2	3	4
TPH2	3	4

Drugs targeting cohort genes (top 30)

Molecule	Max phase	Targets in cohort
BERBERINE	4	TDO2
TELOTRISTAT	4	TPH2
TELOTRISTAT ETHYL	4	TPH2
IMIPRAMINE	4	DRD5
ARIPIPRAZOLE	4	DRD5
AMOXAPINE	4	DRD5
DIHYDROERGOTAMINE MESYLATE	4	DRD5
TEGASEROD MALEATE	4	DRD5
DOPAMINE HYDROCHLORIDE	4	DRD5
PALIPERIDONE	4	DRD5
DOXEPIN	4	DRD5
KETOTIFEN FUMARATE	4	DRD5
CARIPRAZINE	4	DRD5
BREXPIPRAZOLE	4	DRD5
MAPROTILINE	4	DRD5
LASMIDITAN	4	DRD5
CLOZAPINE	4	DRD5
APOMORPHINE	4	DRD5
HALOPERIDOL	4	DRD5
PROMAZINE	4	DRD5
ROPINIROLE	4	DRD5
DOPAMINE	4	DRD5
AMITRIPTYLINE	4	DRD5
CHLORPROMAZINE	4	DRD5
OLANZAPINE	4	DRD5
FLUPHENAZINE	4	DRD5
LOXAPINE	4	DRD5
RISPERIDONE	4	DRD5
CHLORPROTHIXENE	4	DRD5
CABERGOLINE	4	DRD5

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 2.

Cohort genes with ChEMBL bioactivity (full, sorted by assay count)

Symbol	Assays	Type breakdown
DRD5	313	Binding:280, Functional:28, ADMET:5
TDO2	152	Binding:152
TPH2	7	Binding:6, ADMET:1

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
TDO2	1.13.11.11, 1.13.11.52	tryptophan 2,3-dioxygenase, indoleamine 2,3-dioxygenase
TPH2	1.14.16.4	tryptophan 5-monooxygenase

Cohort genes with high screening signal

≥100 ChEMBL assays — a studied-ness signal; see Therapeutics for approved-drug status.

Symbol	ChEMBL assays
TDO2	152
DRD5	313

Pharmacogenomics

Cohort genes with a PharmGKB record: 3; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

30 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Compound	Max phase	Cohort target (bioactivity)
BERBERINE	4	TDO2
TELOTRISTAT	4	TPH2
TELOTRISTAT ETHYL	4	TPH2
IMIPRAMINE	4	DRD5
ARIPIPRAZOLE	4	DRD5
AMOXAPINE	4	DRD5
DIHYDROERGOTAMINE MESYLATE	4	DRD5
TEGASEROD MALEATE	4	DRD5
DOPAMINE HYDROCHLORIDE	4	DRD5
PALIPERIDONE	4	DRD5
DOXEPIN	4	DRD5
KETOTIFEN FUMARATE	4	DRD5
CARIPRAZINE	4	DRD5
BREXPIPRAZOLE	4	DRD5
MAPROTILINE	4	DRD5
LASMIDITAN	4	DRD5
CLOZAPINE	4	DRD5
APOMORPHINE	4	DRD5
HALOPERIDOL	4	DRD5
PROMAZINE	4	DRD5
ROPINIROLE	4	DRD5
DOPAMINE	4	DRD5
AMITRIPTYLINE	4	DRD5
CHLORPROMAZINE	4	DRD5
OLANZAPINE	4	DRD5
FLUPHENAZINE	4	DRD5
LOXAPINE	4	DRD5
RISPERIDONE	4	DRD5
CHLORPROTHIXENE	4	DRD5
CABERGOLINE	4	DRD5

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	3	TDO2, TPH2, DRD5
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	0

Undrugged target profiles

0 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Clinical trials & evidence

Clinical trials

Clinical trials: 0.